The analyst following ACR at BBY has reiterated his "Strong Buy recommendation" after todays announcement. Denis Hulme says "the patent news will prevent competitors developing an underarm testerone delivery technology until at least 2027 while strenghtening the protection of Acrux's drug Axiron against generic competition" and this is the clincher as far as I'm concerned...."importantly the patent gives greater certainty around future Axiron revenues and increases the likelihood that Lilly will make a bid for ACR"
Hulme has put his $4.20 price target under review.
Will be interesting as to his reviewed price, things are looking very promising for ACR.
Add to My Watchlist
What is My Watchlist?
